Spain’s competition watchdog, CNMC, has started investigation proceedings against Grifols SA, which may face fines and sanctions stemming from their failure to notify authorities of their merger and acquisitions plans.
The CNMC authorized the first phase of Grifols takeover of Novartis International’s blood transfusion diagnostics division, which was bought by the Spanish multinational on March 25. However, the CNMC would have received the formal notification documents only ten days prior, on March 10th.
The relevant merger operations, meanwhile, would have taken place over one year prior, in early January 2014. Spain’s competition laws force businesses to notify the CNMC of any merger before it is carried out. Due to the timeline presented to the regulator, the CNMC has determined it necessary to investigate whether or not this rule was violated by the pharmaceuticals multinational.
Full content: CNMC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI